Portal vein thrombosis
diseaseOn this page
Also known as portal vein thrombotic diseasethrombotic disease of portal vein
Summary
Portal vein thrombosis (MONDO:0001339) is a disease and 60 clinical trials. Top therapeutic interventions include nadroparin calcium, enoxaparin sodium, and propranolol. A subtype of thrombotic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 60
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | portal vein thrombosis |
| Mondo ID | MONDO:0001339 |
| DOID | DOID:11695 |
| ICD-10-CM | I81 |
| ICD-11 | 866276949 |
| NCIT | C78565 |
| SNOMED CT | 17920008 |
| UMLS | C0155773 |
| MedGen | 56372 |
| Anatomy (UBERON) | UBERON:0002017 |
| Is cancer (heuristic) | no |
Also known as: portal vein thrombotic disease · thrombotic disease of portal vein
Disease family
This is a subtype of thrombotic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › thrombotic disease › portal vein thrombosis
Related subtypes (7): marantic endocarditis, intracranial thrombosis, coronary thrombosis, heparin-induced thrombocytopenia, acquired purpura fulminans, isolated splenic vein thrombosis, isolated mesenteric vein thrombosis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 60.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 38 |
| PHASE3 | 8 |
| PHASE4 | 7 |
| PHASE2 | 5 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07132515 | PHASE4 | RECRUITING | Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC |
| NCT07521332 | PHASE4 | RECRUITING | Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis |
| NCT02398357 | PHASE4 | UNKNOWN | The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis |
| NCT02630095 | PHASE4 | UNKNOWN | The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT |
| NCT04173429 | PHASE4 | COMPLETED | Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis |
| NCT04976543 | PHASE4 | COMPLETED | Safety of Anticoagulant Therapy After Endoscopic Treatment |
| NCT07571460 | PHASE4 | COMPLETED | Clinical Application of Simcyp-Guided Warfarin Initiation Doses in Cirrhotic Patients With Portal Vein Thrombosis |
| NCT06818279 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis |
| NCT01095185 | PHASE3 | COMPLETED | Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding |
| NCT02250391 | PHASE3 | COMPLETED | Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis |
| NCT02555111 | PHASE3 | COMPLETED | Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. |
| NCT02585713 | PHASE3 | COMPLETED | Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism |
| NCT02627053 | PHASE3 | UNKNOWN | Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study |
| NCT02853526 | PHASE3 | UNKNOWN | TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV |
| NCT03193502 | PHASE3 | UNKNOWN | Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis |
| NCT04387695 | PHASE3 | UNKNOWN | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT |
| NCT00769873 | PHASE2 | TERMINATED | Anticoagulation Post Laparoscopic Splenectomy |
| NCT03009461 | PHASE2 | COMPLETED | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis |
| NCT05166239 | PHASE2 | COMPLETED | HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT |
| NCT05625893 | PHASE2 | COMPLETED | Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion |
| NCT05872841 | PHASE2 | UNKNOWN | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis |
| NCT04055389 | PHASE1 | WITHDRAWN | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis |
| NCT05782556 | Not specified | RECRUITING | Freiburg TIPS Registry |
| NCT06122753 | Not specified | NOT_YET_RECRUITING | Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis |
| NCT06319131 | Not specified | NOT_YET_RECRUITING | Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT |
| NCT06513780 | Not specified | RECRUITING | A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation |
| NCT07062289 | Not specified | NOT_YET_RECRUITING | Endoscopic Ultrasound-guided Measurement of Portal Vein Pressure Gradient |
| NCT07422701 | Not specified | NOT_YET_RECRUITING | Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation |
| NCT07461532 | Not specified | RECRUITING | Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD |
| NCT07461545 | Not specified | RECRUITING | Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS |
| NCT07473375 | Not specified | RECRUITING | Indicators Affecting PVT Recanalization |
| NCT07560202 | Not specified | ACTIVE_NOT_RECRUITING | Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors |
| NCT07602062 | Not specified | NOT_YET_RECRUITING | Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis |
| NCT01326949 | Not specified | COMPLETED | Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis |
| NCT01470547 | Not specified | COMPLETED | Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry |
| NCT01556282 | Not specified | COMPLETED | TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis |
| NCT01631877 | Not specified | WITHDRAWN | Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver |
| NCT01690715 | Not specified | TERMINATED | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery |
| NCT02069457 | Not specified | COMPLETED | Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis |
| NCT02485184 | Not specified | UNKNOWN | TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NADROPARIN CALCIUM | 4 | 5 |
| ENOXAPARIN SODIUM | 4 | 3 |
| PROPRANOLOL | 4 | 3 |
| APIXABAN | 4 | 2 |
| CHLOROTRIANISENE | 4 | 2 |
| CARVEDILOL | 4 | 1 |
| DABIGATRAN ETEXILATE | 4 | 1 |
| DALTEPARIN SODIUM | 4 | 1 |
| SORAFENIB | 4 | 1 |
| WARFARIN | 4 | 1 |
| DABIGATRAN | 3 | 2 |
| ANTITHROMBIN III HUMAN | 3 | 1 |
| DEXPROPRANOLOL | 2 | 1 |
| (R)-Carvedilol | 0 | 1 |
| ENOXAPARIN | 0 | 1 |